Ferring Pharmaceuticals
Pfizer’s PADCEV gets FDA approval for bladder cancer
Bladder cancer affects more than 614,000 people globally each year
Lilly and MeiraGTx partner in $475m ophthalmology deal
The companies will develop and commercialise therapies for genetic conditions
Merck and Blackstone agree on funding for cancer protein antibody
The funding will support late-stage clinical development of the investigational antibody-drug conjugate
Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer
An estimated 84,870 people will be diagnosed with bladder cancer in the US this year
AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer
More than 35,000 people in five major European countries were treated for the disease last year
AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer
More than 614,000 cases of bladder cancer are diagnosed globally every year
Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC
Almost 1,700 people are diagnosed with bladder cancer in Scotland annually
AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer
Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence
The (clinical) trials and tribulations of gene therapy – why meaningful patient engagement strategies matter
By Sarah Mohamad and Lauren Coleman-Bennett
Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial
As many as half of patients with high-risk NMIBC experience disease recurrence despite BCG treatment
What do people look for in gene therapy materials? Results from our survey of patients and relatives
By Sam Fraser
AstraZeneca’s Imfinzi regimen approved by FDA to treat bladder cancer
Around half of patients who undergo bladder removal surgery experience disease recurrence